Replimune Group Inc. [REPL] shares are up more than 102.71% this year and recently increased 0.22% or $6.91 to settle at $31.60. REPL has a short ratio of 3.53. This implies that the market is currently less bullish on the outlook for REPL.

On 7, August 2020, Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update. According to news published on Yahoo Finance, Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory melanoma .

Analyst Birdseye View:

The most recent analyst activity for Replimune Group Inc. [NASDAQ:REPL] stock was on May 05, 2020, when it was Initiated with an Overweight rating from Barclays, which also raised its 12-month price target on the stock to $21. Before that, on July 01, 2020, H.C. Wainwright Recapitulated a Neutral rating and elevated its amount target to $25. On September 04, 2019, ROTH Capital Initiated a Buy rating and boosted its price target on this stock to $20. On July 23, 2019, Chardan Capital Markets Initiated a Buy rating and increased its price target to $28. On July 12, 2019, JP Morgan Upgrade an Overweight rating and decreased its price target to $26. On July 08, 2019, H.C. Wainwright Initiated a Buy rating and boosted its amount on this stock to $26. On April 25, 2019, Wedbush Initiated an Outperform rating and boosted its target amount on this stock to $24.

In the past 52 weeks of trading, this stock has oscillated between a low of $8.58 and a peak of $27.69. Right now, the middling Wall Street analyst 12-month amount mark is $30.00. At the most recent market close, shares of Replimune Group Inc. [NASDAQ:REPL] were valued at $31.60. According to the average price forecast, investors can expect a potential return of -2.5%.


If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 18.53 and the whole liability to whole assets at 17.85. It shows enduring liability to the whole principal at 17.07 and enduring liability to assets at 0.16 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 24.20 points at 1st support level, the second support level is making up to 23.70. But as of 1st resistance point, this stock is sitting at 25.15 and at 25.60 for 2nd resistance point.

Replimune Group Inc. [REPL] reported its earnings at -$0.44 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.46/share signifying the difference of 0.02 and 4.30% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.41 calling estimates for -$0.45/share with the difference of 0.04 depicting the surprise of 8.90%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Replimune Group Inc. [NASDAQ:REPL] is 22.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 14.20. Now if looking for a valuation of this stock’s amount to book ratio is 1.99.

Insider Stories

The most recent insider trade was by Love Colin, Chief Operating Officer, and it was the sale of 15000.0 shares on Sep 15. Esposito Pamela, the Chief Business Officer, completed a sale of 5000.0 shares on Aug 31. On Aug 17, Love Colin, Chief Operating Officer, completed a sale of 15000.0 shares.